DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix.NCCN Cutaneous Melanoma Guidelines ...

CereVasc, Inc. Announces Publication of A Multi-Center Study Evaluating the eShunt® System in the Treatment of Patients with NPH

CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, today announced results from a prospective, multi-center, single-arm clinical study ...
WIBC 93.1 FM

Sleep Duration Directly Impacts Atrial Fibrillation Risk, Study Finds

Atrial fibrillation is the most common form of heart rhythm disorder and is linked to serious complications, including stroke ...
ascopubs.org

Efficacy and safety of atezolizumab and bevacizumab with or without transarterial chemoembolization as first-line therapy for advanced hepatocellular carcinoma: An ...

Radiomic analysis on pretreatment MRI to predict response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma: A multicenter study. This is an ASCO Meeting Abstract from the 2025 ...

Prospective Multicenter Registry Study Reports High Local Tumor Control Following Resection with GammaTile® in Newly Diagnosed Brain Metastases

GT Medical Technologies, Inc., a company focused on improving the lives of patients with brain tumors, today announced a publication of prospective, multicenter Phase IV data from the ongoing ...
ascopubs.org

Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK)

This multicenter, prospective study (ClinicalTrials.gov identifier: NCT04703153) enrolled patients across the United States and Singapore. Patients were tested with tissue NGS, LHM, and G360 ctDNA.